CDC flags neuro symptoms after unapproved botulinum toxin

• by Teraya Smith

• October 9, 2026

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Safety and Efficacy of OBI-858 in Patients with Moderate-to-Severe Glabellar Lines

• by Yu-Hsiu Yen, Tzu-Wen Tsau, Chih-Hung Lee, Hsin-Han Chen, Chih-Hung Lin, Tim-Mo Chen, Chi-Ming Pu

• November 1, 2025

Consensus Guidelines for Dermocosmetic Ingredient Selection in Common Dermatological Situations in Egypt: A RAND/UCLA Appropriateness Assessment

• by Mahmoud A. Rageh, Wael M. Seoudy, Mohamed F. Abozeid, Abeer Mohamed Elkholy, Alaa E. A. Moubasher, Amany Mohammad Abdel-Latif, Dalia Abdel Aziz Attallah, Essamelden M. Mohamed, Hanan Abdelrady Assaf, Hanan Sabry, Mohamed Mahmoud Nasr, Mohamed Saad Hegazy, Nahla Hunter, Nehal Zuelfakkar, Nermeen Ibrahim Bedair, Noha Ezzat Mohammed, Sameh F. Abdelkodous, Yasser Mostafa Gohary, Sara M. Mohy

• January 15, 2026

AOPT Plus Collagen May Ease Rosacea

Randomized trial suggests better short-term outcomes and lower recurrence at 24 weeks.

• by Andrea Surnit

• May 13, 2026

• 3 min